TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01158729

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antithrombin (Recombinant)
Description: Single dose of antithrombin (recombinant) to be given prior to initiation of cardiopulmonary bypass. Intravenous dose determined by following formula: ATIII dose given to patient = \[(1.0 Units/mL - patient's measured ATIII concentration in Units/mL) X weight (kg) X 80 mL/kg\] X (1 mL/175 Units)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single dose of placebo (0.9% NaCl) to be given prior to initiation of cardiopulmonary bypass. Intravenous dose determined by following formula: Placebo dose given to patient = \[(1.0 Units/mL - patient's measured ATIII concentration in Units/mL) X weight (kg) X 80 mL/kg\] X (1 mL/175 Units)
Study: NCT04369755

Intervention type: OTHER
Group type: OTHER
Intervention: MRI
Description: A MRI in PTX mode will be done on healthy subject (approx. 90 min of sequences)
Study: NCT03052439

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: FODMAP
Description: After 2 weeks on a low FODMAP diet, subject will undergo a reintroduction period. 5 different FODMAPs will be reintroduced (1 week at a time, followed by 1 week washout) in a blinded, randomized fashion.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: FODMAP
Description: After 2 weeks on a low FODMAP diet, subject will undergo a reintroduction period. 5 different FODMAPs will be reintroduced (1 week at a time, followed by 1 week washout) in a blinded, randomized fashion.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: FODMAP
Description: After 2 weeks on a low FODMAP diet, subject will undergo a reintroduction period. 5 different FODMAPs will be reintroduced (1 week at a time, followed by 1 week washout) in a blinded, randomized fashion.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: FODMAP
Description: After 2 weeks on a low FODMAP diet, subject will undergo a reintroduction period. 5 different FODMAPs will be reintroduced (1 week at a time, followed by 1 week washout) in a blinded, randomized fashion.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: FODMAP
Description: After 2 weeks on a low FODMAP diet, subject will undergo a reintroduction period. 5 different FODMAPs will be reintroduced (1 week at a time, followed by 1 week washout) in a blinded, randomized fashion.
Study: NCT04990661

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: intradialytic massage
Description: intradialytic massage for lower extremity ( the massage included both feet and legs up to and including the knee) applied to the intervention group in three sessions a week and a total of six sessions for two weeks
Study: NCT04436874

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: endoscopy
Description: transplant infusion of feces from healthy donors into affected subjects

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: endoscopy
Description: transplant infusion of feces from healthy donors into affected subjects

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: endoscopy
Description: transplant infusion of feces from healthy donors into affected subjects
Study: NCT02941276

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active Electrostimulator device
Description: Patients who will receive a fully functioning device
Study: NCT04436874

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: endoscopy
Description: transplant infusion of feces from healthy donors into affected subjects
Study: NCT02627521

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor
Description: Ticagrelor administration prior to randomization
Study: NCT00305604

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sitagliptin phosphate
Description: Once daily (q.d.) administration of sitagliptin 100 mg tablet (or 50 mg based on creatinine clearance). For up to a 24-wk treatment period.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: Placebo
Description: sitagliptin matching placebo for up to a 24-wk treatment period.
Study: NCT05915936

Intervention type: PROCEDURE
Intervention: LVMR
Description: laoparoscopic ventral mesh rectopexy

Intervention type: PROCEDURE
Intervention: PSR
Description: perineal stapler resection
Study: NCT02146248

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: combined oral contraceptive
Description: combined oral contraceptive pill will be dosed continuously for 30 days without cycle interruption

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DepoProvera
Description: injectable hormonal contraceptive
Study: NCT01249534

Intervention type: OTHER
Intervention: gastroesophageal cancer surgery
Description: gastroesophageal cancer surgery
Study: NCT04093362

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAS-120
Description: TAS-120 is an oral FGFR inhibitor

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin/Gemcitabine
Description: Cisplatin/Gemcitabine is currently 1st line standard of care
Study: NCT04381429

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: A-F-A-F (NovoRapid-FIASP-NovoRapid-FIASP)
Description: A = pre-prandial aspart insulin (NovoRapid) F = post prandial Faster-acting aspart insulin (FIASP)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: F-A-F-A (FIASP-NovoRapid-FIASP-NovoRapid)
Description: A = pre-prandial aspart insulin (NovoRapid) F = post prandial Faster-acting aspart insulin (FIASP)
Study: NCT03617367

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: daxibotulinumtoxinA for injection
Description: DaxibotulinumtoxinA for injection is a sterile, white to off-white lyophilized product containing the active ingredient, daxibotulinumtoxinA, and inactive ingredients to be reconstituted with sterile, non-preserved, 0.9% sodium chloride solution saline.
Study: NCT01259973

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risperidone
Description: 1 single dose of 2.5mg masked in 250 mL of peach juice, for 1 day. Oral administration.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 single dose of 2.5mL physiological serum masked in 250 mL of peach juice, for 1 day. Oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Haloperidol
Description: 1 single dose of 5mg masked in 250 mL of peach juice, for 1 day. Oral administration.
Study: NCT04092816

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FAMILY Intervention
Description: The FAMILY intervention involves 2-3 study visits with a specially-trained intervention facilitator. Study visits are manualized and complemented by patient education materials.
Study: NCT04569916

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiotherapy
Description: radiotherapy combined with irinotecan liposome and apatinib followed by PD-1 antibody and apatinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan liposome
Description: radiotherapy combined with irinotecan liposome and apatinib followed by PD-1 antibody and apatinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: apatinib
Description: radiotherapy combined with irinotecan liposome and apatinib followed by PD-1 antibody and apatinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1 antibody
Description: radiotherapy combined with irinotecan liposome and apatinib followed by PD-1 antibody and apatinib
Study: NCT01422590

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin
Description: Single oral administration of sitagliptin 100 mg
Study: NCT02941276

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Electrostimulator device
Description: Patients who will receive a device that does not release electric stimuli (but provided mechanical/tactile stimulation)
Study: NCT00944112

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Restrictive RBC Transfusion
Description: Patients will receive single unit RBC transfusions with a transfusion trigger of ≤70 g/L with a target Hb concentration of 71-90 g/L during the intervention period.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Liberal RBC Transfusion
Description: Patients will receive single unit RBC transfusions with a transfusion trigger of ≤90 g/L with a target Hb concentration of 91-110 g/L during intervention.
Study: NCT01589861

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BKM120 + lapatinib
Description: BKM120 40, 60 or 80 mg/day per os for 28 days cycle associated to lapatinib 750, 1000 or 1250 mg/day per os for 28 days cycle until progression or toxicity
Study: NCT02147249

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: antibiotic treatment
Description: Patient will be treated with: doxycycline orally, 100 mg, bid, 14 days or cefuroxime axetil orally, 500 mg, bid, 14 days or amoxicillin orally, 500 mg, tid, 14 days
Study: NCT01762124

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Native Outflow Tract TPV
Description: Transcatheter placement of a pulmonary valve
Study: NCT04565509

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: General Communication Message
Description: A messaging strategy will be developed from focus groups that generally describes COVID-19 and the importance of testing.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Focused/Targeted Message
Description: A messaging strategy that is developed from focus groups that is targeted to address specific concerns of the different communities. Messages may target groups being tested (staff versus students) or sociodemographic or race/ethnicity differences between schools depending on the focus groups input.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Best Message Alone
Description: The best message will be either the general or focused/targeted message described above.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Best Message + Augmented Message or Implementation Strategy
Description: The augmented messaging and implementation strategies will be informed by the barriers and facilitators identified based on the CFIR domains and results of focus groups and surveys in Aim 2.
Study: NCT00265850

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: bevacizumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cetuximab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cetuximab
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FOLFOX or
Description: Patients receive oxaliplatin 85 mg/m\^2 IV infused over two hours followed by leucovorin 400 mg/m\^2 IV over 2 hours followed by 5-FU 400 mg/m\^2 IV bolus, then 2400 mg/m\^2 continuous IV infusion over 46-48 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX or
Description: Patients receive oxaliplatin 85 mg/m\^2 IV infused over two hours followed by leucovorin 400 mg/m\^2 IV over 2 hours followed by 5-FU 400 mg/m\^2 IV bolus, then 2400 mg/m\^2 continuous IV infusion over 46-48 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX or
Description: Patients receive oxaliplatin 85 mg/m\^2 IV infused over two hours followed by leucovorin 400 mg/m\^2 IV over 2 hours followed by 5-FU 400 mg/m\^2 IV bolus, then 2400 mg/m\^2 continuous IV infusion over 46-48 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FOLFIRI
Description: Patients receive irinotecan 180 mg/m\^2 IV infused over 90 minutes followed by leucovorin 400 mg/m\^2 IV over 2 hours followed by 5-FU 400 mg/m\^2 IV bolus following leucovorin then 2400 mg/m\^2 continuous IV infusion over 46-48 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRI
Description: Patients receive irinotecan 180 mg/m\^2 IV infused over 90 minutes followed by leucovorin 400 mg/m\^2 IV over 2 hours followed by 5-FU 400 mg/m\^2 IV bolus following leucovorin then 2400 mg/m\^2 continuous IV infusion over 46-48 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRI
Description: Patients receive irinotecan 180 mg/m\^2 IV infused over 90 minutes followed by leucovorin 400 mg/m\^2 IV over 2 hours followed by 5-FU 400 mg/m\^2 IV bolus following leucovorin then 2400 mg/m\^2 continuous IV infusion over 46-48 hours.
Study: NCT02627521

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Description: Ticagrelor administration prior to randomization
Study: NCT00549081

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: DHEA
Description: oral DHEA tablets 75 mg daily
Study: NCT04282824

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of saliva

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo PET/CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo PET/CT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gallium Ga 68-labeled PSMA-11
Description: Given IV
Study: NCT01422590

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mitiglinide
Description: Single oral administration of mitiglinide 10 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin, Mitiglinide
Description: Concomitant administration of sitagliptin 100 mg and mitiglinide 10 mg
Study: NCT03583320

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Cardiac CT angiogram
Description: To the best of the author's knowledge this study will provide the first prospective and randomised data pertaining to hospital length of stay as a primary outcome in the use of CTCA on this acute chest pain cohort (with an intermediate observational zone category) on initial high sensitivity-cardiac troponin (hs-cTn) results presenting to the emergency department in a tertiary care hospital.
Study: NCT04229784

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiofrewuency surgery
Description: The research procedure consists of radiofrequency destruction of hemorrhoidal vascular tissue. It consists in delivering a 4 MHz radiofrequency wave current delivered at low temperature by microfibre electrodes using a large disposable needle within the hemorrhoidal vascular tissue
Study: NCT01665924

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG0634 100mg capsule once a day for 10 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG0634 100mg capsule once a day for 10 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG0634 100mg capsule once a day for 10 days
Study: NCT01202812

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega-3 Fatty Acids: Eicosapentaenoic Acid (EPA) and Docosahexaenoic Acid (DHA)
Description: Eicosapentaenoic Acid (EPA)/Docosahexaenoic Acid (DHA) 30mg/kg (LOVAZA capsules) given by mouth daily for 6 months.
Study: NCT04282824

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gallium Ga 68-labeled PSMA-11
Description: Given IV
Study: NCT01202812

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Capsules
Description: Placebo capsules given by mouth daily for 6 months.
Study: NCT05517915

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training.
Description: Interval inspiratory muscle training was performed using the inspiratory muscle trainer.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham inspiratory muscle training.
Description: Interval inspiratory muscle training was performed using the unloaded inspiratory muscle trainer.
Study: NCT04425512

Intervention type: DIAGNOSTIC_TEST
Group type: SHAM_COMPARATOR
Intervention: Complete Blood Count
Description: Complete Blood Count samples

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Complete Blood Count
Description: Complete Blood Count samples

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Complete Blood Count
Description: Complete Blood Count samples
Study: NCT02407041

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GR-MD-02
Description: IV infusion
Study: NCT02601443

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cervical Pessary
Study: NCT02567617

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Polyphenols
Description: Capsules with five substances (polyphenols) at a concentration of 3000mg per day

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo controlled
Description: Starch capsules
Study: NCT03402152

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NRX-101
Description: NRX-101, a fixed dose combination of D-cycloserine+lurasidone will be given twice a day by mouth

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NRX-101
Description: NRX-101, a fixed dose combination of D-cycloserine+lurasidone will be given twice a day by mouth

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lurasidone HCl
Description: Lurasidone HCl will be given twice a day by mouth

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo oral capsule
Study: NCT00823524

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: donor natural killer cell infusion
Description: give patients donor-derived NK cells 2 to 3 weeks after HLA-haploidentical hematopoietic cell transplantation
Study: NCT01196650

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IN 10 003 formulation A

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IN 10 003 formulation B

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsules
Study: NCT00789191

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin detemir
Description: The detemir insulin dose is injected subcutaneously (under the skin) once daily in the evening and will be titrated (individually adjusted) weekly throughout the trial.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sitagliptin
Description: The sitagliptin dose is 100 mg/ day and should be kept stable throughout the trial. Frequency of sitagliptin is once daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sitagliptin
Description: The sitagliptin dose is 100 mg/ day and should be kept stable throughout the trial. Frequency of sitagliptin is once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin
Description: Metformin treatment with at least 1000 mg/ day. Dose and dosing frequency should remain unchanged throughout the trial.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metformin
Description: Metformin treatment with at least 1000 mg/ day. Dose and dosing frequency should remain unchanged throughout the trial.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sulphonylurea
Description: Sulphonylurea (SU) dose and dosing frequency should initially remain unchanged. In case of hypoglycaemia SU dose may be reduced at the discretion of the investigator.
Study: NCT03006471

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: 10 mg, one per day before breakfast during 12 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - Cap
Description: one per day before breakfast during 12 weeks.
Study: NCT02284685

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Promoting Eating Disorder Treatment among College Students
Description: Online intervention designed to identify and increase help-seeking among undergraduates with previously undiagnosed/untreated eating disorders

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Promoting Eating Disorder Treatment among College Students
Description: Online intervention designed to identify and increase help-seeking among undergraduates with previously undiagnosed/untreated eating disorders

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Promoting Eating Disorder Treatment among College Students
Description: Online intervention designed to identify and increase help-seeking among undergraduates with previously undiagnosed/untreated eating disorders

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Promoting Eating Disorder Treatment among College Students
Description: Online intervention designed to identify and increase help-seeking among undergraduates with previously undiagnosed/untreated eating disorders

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Promoting Eating Disorder Treatment among College Students
Description: Online intervention designed to identify and increase help-seeking among undergraduates with previously undiagnosed/untreated eating disorders

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Promoting Eating Disorder Treatment among College Students
Description: Online intervention designed to identify and increase help-seeking among undergraduates with previously undiagnosed/untreated eating disorders

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Promoting Eating Disorder Treatment among College Students
Description: Online intervention designed to identify and increase help-seeking among undergraduates with previously undiagnosed/untreated eating disorders

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Promoting Eating Disorder Treatment among College Students
Description: Online intervention designed to identify and increase help-seeking among undergraduates with previously undiagnosed/untreated eating disorders
Study: NCT01009983

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: panitumumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative study

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: immunohistochemistry staining method
Description: Correlative study
Study: NCT00223691

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atomoxetine
Description: 10-50 mg, PO. Single dose. Alone or in combination with Yohimbine or Mestinon.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acarbose
Description: 25-100 mg, PO. Single dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyridostigmine Bromide
Description: 30 mg-180 mg PO. Single dose. Alone or in combination with Yohimbine or atomoxetine.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Yohimbine
Description: 2.7, 5.4 or 10.8 mg PO. Single dose. Alone or in combination with Atomoxetine or Pyridostigmine.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midodrine HCl
Description: 2.5, 5.0, 7.5, 10 mg PO. Single dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: PO.Single dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Modafinil
Description: 50-400 mg PO. Single dose
Study: NCT04282824

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Monosodium Glutamate
Description: Given PO